Risk of fracture and osteonecrosis by clinical and genetic reclassified race/ethnicity in the genotyped subcohort of the DFCI 05-001 trial
| Race/ethnicity . | No. of bone toxicities (%) . | Unadjusted model . | Adjusted model* . | |||
|---|---|---|---|---|---|---|
| Yes . | No . | SHR (95% CI) . | P . | SHR (95% CI) . | P . | |
| Fractures | ||||||
| Clinical | ||||||
| White | 88 (79.3) | 206 (60.9) | 1.00 | 1.00 | ||
| Hispanic | 10 (9.0) | 64 (18.9) | 0.42 (0.22-0.81) | .009 | 0.39 (0.21-0.73) | .003 |
| Black | 1 (0.9) | 19 (5.6) | 0.15 (0.02-1.09) | .06 | 0.15 (0.02-1.06) | .06 |
| Asian | 2 (1.8) | 13 (3.8) | 0.43 (0.10-1.78) | .24 | 0.45 (0.11-1.95) | .29 |
| Other | 10 (9.0) | 36 (10.7) | 0.68 (0.36-1.29) | .24 | 0.79 (0.42-1.50) | .47 |
| Genetically reclassified | ||||||
| White | 92 (82.9) | 213 (63.0) | 1.00 | 1.00 | ||
| Hispanic | 10 (9.0) | 64 (18.9) | 0.43 (0.22-0.84) | .01 | 0.42 (0.22-0.81) | .01 |
| Black | 4 (3.6) | 35 (10.4) | 0.32 (0.12-0.86) | .02 | 0.28 (0.10-0.75) | .01 |
| Asian | 4 (3.6) | 22 (6.5) | 0.50 (0.18-1.36) | .17 | 0.47 (0.16-1.33) | .15 |
| Other | 1 (0.9) | 4 (1.2) | 0.59 (0.10-3.74) | .59 | 0.81 (0.13-5.17) | .82 |
| Osteonecrosis | ||||||
| Clinical | ||||||
| White | 38 (84.4) | 256 (63.4) | 1.00 | 1.00 | ||
| Hispanic | 3 (6.7) | 71 (17.6) | 0.30 (0.09-0.96) | .04 | 0.20 (0.06-0.65) | .008 |
| Black | 0 | 20 (5.0) | NA | NA | NA | NA |
| Asian | 0 | 15 (3.7) | NA | NA | NA | NA |
| Other | 4 (8.9) | 42 (10.4) | 0.66 (0.23-1.85) | .43 | 0.90 (0.34-2.37) | .83 |
| Genetically reclassified | ||||||
| White | 40 (88.9) | 265 (65.6) | 1.00 | 1.00 | ||
| Hispanic | 3 (6.7) | 71 (17.6) | 0.30 (0.09-0.96) | .04 | 0.24 (0.08-0.78) | .02 |
| Black | 1 (2.2) | 38 (9.4) | 0.18 (0.03-1.32) | .09 | 0.12 (0.02-0.93) | .04 |
| Asian | 1 (2.2) | 25 (6.2) | 0.28 (0.04-2.02) | .21 | 0.12 (0.03-1.47) | .12 |
| Other | 0 | 5 (1.2) | NA | NA | NA | NA |
| Race/ethnicity . | No. of bone toxicities (%) . | Unadjusted model . | Adjusted model* . | |||
|---|---|---|---|---|---|---|
| Yes . | No . | SHR (95% CI) . | P . | SHR (95% CI) . | P . | |
| Fractures | ||||||
| Clinical | ||||||
| White | 88 (79.3) | 206 (60.9) | 1.00 | 1.00 | ||
| Hispanic | 10 (9.0) | 64 (18.9) | 0.42 (0.22-0.81) | .009 | 0.39 (0.21-0.73) | .003 |
| Black | 1 (0.9) | 19 (5.6) | 0.15 (0.02-1.09) | .06 | 0.15 (0.02-1.06) | .06 |
| Asian | 2 (1.8) | 13 (3.8) | 0.43 (0.10-1.78) | .24 | 0.45 (0.11-1.95) | .29 |
| Other | 10 (9.0) | 36 (10.7) | 0.68 (0.36-1.29) | .24 | 0.79 (0.42-1.50) | .47 |
| Genetically reclassified | ||||||
| White | 92 (82.9) | 213 (63.0) | 1.00 | 1.00 | ||
| Hispanic | 10 (9.0) | 64 (18.9) | 0.43 (0.22-0.84) | .01 | 0.42 (0.22-0.81) | .01 |
| Black | 4 (3.6) | 35 (10.4) | 0.32 (0.12-0.86) | .02 | 0.28 (0.10-0.75) | .01 |
| Asian | 4 (3.6) | 22 (6.5) | 0.50 (0.18-1.36) | .17 | 0.47 (0.16-1.33) | .15 |
| Other | 1 (0.9) | 4 (1.2) | 0.59 (0.10-3.74) | .59 | 0.81 (0.13-5.17) | .82 |
| Osteonecrosis | ||||||
| Clinical | ||||||
| White | 38 (84.4) | 256 (63.4) | 1.00 | 1.00 | ||
| Hispanic | 3 (6.7) | 71 (17.6) | 0.30 (0.09-0.96) | .04 | 0.20 (0.06-0.65) | .008 |
| Black | 0 | 20 (5.0) | NA | NA | NA | NA |
| Asian | 0 | 15 (3.7) | NA | NA | NA | NA |
| Other | 4 (8.9) | 42 (10.4) | 0.66 (0.23-1.85) | .43 | 0.90 (0.34-2.37) | .83 |
| Genetically reclassified | ||||||
| White | 40 (88.9) | 265 (65.6) | 1.00 | 1.00 | ||
| Hispanic | 3 (6.7) | 71 (17.6) | 0.30 (0.09-0.96) | .04 | 0.24 (0.08-0.78) | .02 |
| Black | 1 (2.2) | 38 (9.4) | 0.18 (0.03-1.32) | .09 | 0.12 (0.02-0.93) | .04 |
| Asian | 1 (2.2) | 25 (6.2) | 0.28 (0.04-2.02) | .21 | 0.12 (0.03-1.47) | .12 |
| Other | 0 | 5 (1.2) | NA | NA | NA | NA |
NA, not available; SHR, subdistribution hazard ratio.
Death and recurrence were considered competing risks. Adjusted covariates included age, sex, and final risk group.